Jeremy Rupon

1.2k total citations
35 papers, 797 citations indexed

About

Jeremy Rupon is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Jeremy Rupon has authored 35 papers receiving a total of 797 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 12 papers in Genetics and 10 papers in Molecular Biology. Recurrent topics in Jeremy Rupon's work include Hemophilia Treatment and Research (22 papers), Virus-based gene therapy research (9 papers) and Hemoglobinopathies and Related Disorders (8 papers). Jeremy Rupon is often cited by papers focused on Hemophilia Treatment and Research (22 papers), Virus-based gene therapy research (9 papers) and Hemoglobinopathies and Related Disorders (8 papers). Jeremy Rupon collaborates with scholars based in United States, France and Canada. Jeremy Rupon's co-authors include Gerd A. Blobel, Wulan Deng, Laura Breda, Irene Motta, Stefano Rivella, Gordon D. Ginder, Andreas Reik, Philip D. Gregory, Ann Dean and Ivan Krivega and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Jeremy Rupon

32 papers receiving 786 citations

Peers

Jeremy Rupon
Gabriella E. Martyn Australia
Jon Burdach Australia
Ali Aghajanirefah Netherlands
Serena Hou United States
Kai-Hsin Chang United States
Sunmi Han South Korea
Dianne Lumaquin United States
Chiel Maas Netherlands
Alison Slater Australia
R. Wayne Hendren United States
Gabriella E. Martyn Australia
Jeremy Rupon
Citations per year, relative to Jeremy Rupon Jeremy Rupon (= 1×) peers Gabriella E. Martyn

Countries citing papers authored by Jeremy Rupon

Since Specialization
Citations

This map shows the geographic impact of Jeremy Rupon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeremy Rupon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeremy Rupon more than expected).

Fields of papers citing papers by Jeremy Rupon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeremy Rupon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeremy Rupon. The network helps show where Jeremy Rupon may publish in the future.

Co-authorship network of co-authors of Jeremy Rupon

This figure shows the co-authorship network connecting the top 25 collaborators of Jeremy Rupon. A scholar is included among the top collaborators of Jeremy Rupon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeremy Rupon. Jeremy Rupon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kavaklı, Kaan, Adam Cuker, Laurent Frenzel, et al.. (2025). Health-related quality of life in adults with hemophilia B after gene therapy with fidanacogene elaparvovec: results from the BENEGENE-2 trial. Journal of Thrombosis and Haemostasis. 24(1). 132–145.
2.
Rasko, John E.J., Benjamin J. Samelson‐Jones, Lindsey A. George, et al.. (2025). Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study. New England Journal of Medicine. 392(15). 1508–1517. 5 indexed citations
3.
Leavitt, Andrew D., Kaan Kavaklı, Laurent Frenzel, et al.. (2024). Efficacy and Safety of Giroctocogene Fitelparvovec in Adults with Moderately Severe to Severe Hemophilia Α: Primary Analysis Results from the Phase 3 ΑFFINE Gene Therapy Trial. Blood. 144(Supplement 1). 1053–1053. 2 indexed citations
4.
5.
Frenzel, Laurent, Kaan Kavaklı, Robert Klamroth, et al.. (2023). Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis. Blood. 142(Supplement 1). 2257–2257. 2 indexed citations
6.
Alzahrani, Hazzaa, Adam Cuker, Όλγα Κατσαρού, et al.. (2023). PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec. Research and Practice in Thrombosis and Haemostasis. 7. 101217–101217. 1 indexed citations
7.
Cuker, Adam, Hazzaa Alzahrani, Jan Astermark, et al.. (2023). OC 52.3 Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Results from the Phase 3 BENEGENE-2 Gene Therapy Trial. Research and Practice in Thrombosis and Haemostasis. 7. 100452–100452. 2 indexed citations
8.
Rangarajan, Savita, M. Joseph John, Shashikant Apte, et al.. (2022). Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India. Indian Journal of Hematology and Blood Transfusion. 39(4). 624–629.
9.
Rangarajan, Savita, M. Joseph John, Shashikant Apte, et al.. (2022). Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India. Indian Journal of Hematology and Blood Transfusion. 39(4). 630–634.
10.
Visweshwar, Nathan, Thomas J. Harrington, Andrew D. Leavitt, et al.. (2021). Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood. 138(Supplement 1). 564–564. 16 indexed citations
11.
Robinson, Mary, Lindsey A. George, Marcus E. Carr, et al.. (2021). Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua. Journal of Thrombosis and Haemostasis. 19(5). 1212–1218. 22 indexed citations
12.
Sullivan, Spencer K., John E.J. Rasko, Adam Giermasz, et al.. (2021). Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy. Blood. 138(Supplement 1). 3975–3975. 22 indexed citations
13.
Yang, Renchi, Yongqiang Zhao, Xuefeng Wang, et al.. (2020). <p>Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies</p>. Journal of Blood Medicine. Volume 11. 439–448. 2 indexed citations
14.
Leavitt, Andrew D., Barbara A. Konkle, Kimo C. Stine, et al.. (2020). Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a. Blood. 136(Supplement 1). 12–12. 21 indexed citations
15.
Breda, Laura, Irene Motta, Wulan Deng, et al.. (2016). Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood. 128(8). 1139–1143. 59 indexed citations
16.
Deng, Wulan, Jeremy Rupon, Ivan Krivega, et al.. (2014). Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping. Cell. 158(4). 849–860. 311 indexed citations
17.
Rupon, Jeremy, Shou Zhen Wang, Merlin Nithya Gnanapragasam, Stefanos Labropoulos, & Gordon D. Ginder. (2011). MBD2 contributes to developmental silencing of the human ε-globin gene. Blood Cells Molecules and Diseases. 46(3). 212–219. 13 indexed citations
18.
Zhang, Ping, et al.. (2005). A functional screen for Krüppel-like factors that regulate the human γ-globin gene through the CACCC promoter element. Blood Cells Molecules and Diseases. 35(2). 227–235. 55 indexed citations
19.
Rupon, Jeremy, et al.. (2002). Iron Nitrosyl Hemoglobin Formation from the Reactions of Hemoglobin and Hydroxyurea. Biochemistry. 41(7). 2466–2474. 40 indexed citations
20.
Rupon, Jeremy, et al.. (2000). The reactions of myoglobin, normal adult hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea. Biophysical Chemistry. 84(1). 1–11. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriella E. Martyn Breakdown of academic impact, for papers by Jon Burdach Breakdown of academic impact, for papers by Ali Aghajanirefah Breakdown of academic impact, for papers by Serena Hou Breakdown of academic impact, for papers by Kai-Hsin Chang Breakdown of academic impact, for papers by Sunmi Han Breakdown of academic impact, for papers by Dianne Lumaquin Breakdown of academic impact, for papers by Chiel Maas Breakdown of academic impact, for papers by Alison Slater Breakdown of academic impact, for papers by R. Wayne Hendren
Rankless by CCL
2026